U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07746544) titled 'Study of Secutrelvir in Participants With COVID-19' on July 17.
Brief Summary: The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Study Start Date: July 20
Study Type: INTERVENTIONAL
Condition:
COVID-19
Intervention:
DRUG: Secutrelvir
Secutrelvir will be administered orally as a tablet.
DRUG: Placebo
Placebo will be administered orally as a tablet.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shionogi
Published by HT Di...